Peramivir Treatment Response in Adults Hospitalized for Influenza-associated Lower Respiratory Tract Infections
Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
Peramivir is the first intravenous neuraminidase inhibitor (NAI) available for treatment of
uncomplicated influenza in adults. Data from placebo-controlled trials in outpatients have
shown antiviral efficacy, safety, and tolerability. Although the unmet need for intravenous
therapy lies mainly with patients hospitalized with complicated diseases, such data are
limited because of feasibility and ethical considerations for placebo-controlled studies.
In this study, the investigators aimed to examine more specifically treatment effects of
peramivir in adults hospitalized with influenza-associated lower respiratory tract
complications (LRTC). Such findings may have important implications on clinical management.